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Summary 
We previously described the synthesis and in vitro antiviral activity of an 
acyclic thiosangivamycin analog (Gupta et al., 1989a). In order to extend these 
initial studies, a new, multi-gram synthesis of 4-amino-7-[(2-hydroxy- 
ethoxy)methyl]pyrrolo[2,3-d]pyrimidine-5-thiocarboxamide (compound 229) 
was achieved in 5 steps from the known 5-amino-2-bromo-3,4-dicyanopyrrole 
in good overall yield. In plaque reduction assays with HCMV, compound 229 
had an IC50 of 7 /~M; in yield reduction assays the If90 was 25 /~M. The 
compound was less active against MCMV, HSV-I, HSV-2, and least active 
against VZV. Concentrations of compound 229 up to 32 pM did not affect the 
growth of KB cells for incubation periods up to 72 h. At 100 /~M, a 
prolongation in population doubling time from 21 h (untreated) to 35 h was 
noted. This inhibition, however, was reversible upon removal of the compound 
suggesting the inhibition was cytostatic rather than cytotoxic. Flow cytometric 
studies with compound 229 in HFF cells revealed an accumulation of cells in S 
*Portions of this study were presented at the Fourth Annual International Conference on Antiviral 
Research, April 1991, New Orleans, LA. 
Abbreviations: HCMV, human cytomegalovirus; HFF, human foreskin fibroblasts; HSV-1 and -2, herpes 
simplex virus types 1 and 2; IC5o or IC9o, 50 or 90% inhibitory concentration; IR, infrared; MCMV, 
murine cytomegalovirus; MEM, minimum essential medium; PFU, plaque forming unit; NMR, nuclear 
magnetic resonance; TLC, thin-layer chromatography; VZV, varicella zoster virus. 
Correspondence to." J.C. Drach, School of Dentistry, University of Michigan, Ann Arbor, MI 48109- 
1078, USA. 
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phase and a concurrent loss of cells in G2/M phase, suggesting an early S phase 
blockage. We conclude there is adequate separation between antiviral activity 
and cytotoxicity to merit further work with this class of pyrrolopyrimidines. 
HCMV; Acyclic nucleosides; Ganciclovir; Cellular-DNA content 
Introduction 
Human cytomegalovirus is the cause of debilitating and often life or sight 
threatening opportunistic infections in patients infected with human immuno- 
deficiency virus and in other immunocompromised patients (Mills and Masur, 
1990; Bowden, 1991). It also is a leading cause of birth defects as a result of 
congenital infection (Demmler, 1991). Currently, the drugs used to treat 
HCMV infections are ganciclovir (DHPG) and the newly approved foscarnet 
(PF). Both drugs, however, suffer from poor oral bioavailability and produce a 
number of adverse effects in both animals and humans (Shepp et al., 1985; 
Collaborative Study Group, 1986). In contrast, acyclovir is relatively non-toxic 
because it is phosphorylated to its corresponding monophosphate by a herpes 
virus encoded thymidine kinase (Elion et al., 1977; Fyfe et al., 1978). 
Unfortunately, acyclovir is not as effective as ganciclovir in inhibiting HCMV 
replication (Crumpacker et al., 1979; Tyms et al., 1981). 
As part of our ongoing research with pyrrolo[2,3-d]pyrimidine nucleosides 
(Tolman et al., 1969), we have designed, synthesized, and evaluated a number 
of new analogs as potential antiviral agents (Townsend et al., 1991). Although 
the parent nucleoside antibiotics tubercidin, toyocamycin, and sangivamycin 
are active against HCMV, they are equally cytotoxic in uninfected cells (Turk 
et al., 1987). In an attempt to limit cytotoxicity, we initiated studies involving 
specific chemical modifications of the nucleoside antibiotics per se. For 
example, we have synthesized a number of acyclic pyrrolo[2,3-d]pyrimidine 
derivatives containing either the acyclovir or ganciclovir side chain as potential 
HCMV agents (Saxena et al., 1988; Pudlo et al., 1988; Gupta et al., 1989a; 
Gupta et al., 1989b; Pudlo et al., 1990). These studies identified a series of 
acyclic bromotubercidins with potent activity against HCMV both in vitro and 
in vivo (Pudlo et al., 1988, 1990; Nassiri et al., 1990, 1991b). The initial antiviral 
evaluation of other compounds also identified a thiosangivamycin analog (4- 
amino-7-[(2-hydroxyethoxymethyl)]pyrrolo[2,3-d]pyrimidine-5-thiocarbox- 
amide, compound 229*) as active against HCMV (ICs0= 11 #M) without the 
severe cytotoxicity observed with toyocamycin and sangivamycin (Gupta et al., 
1989a). To further evaluate the antiviral activity and cytotoxicity of compound 
229, sufficient quantities were required. However, the original synthetic scheme 
described by Gupta (1989a) was not suitable for supplying the multi-gram 
*Referred to as compound 11 by Gupta  et al., 1989a. 
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quantities necessary for our more extensive studies. This prompted us to 
develop an alternate, multi-gram synthesis of compound 229 which facilitated a 
confirmation and extension of antiviral and cytotoxicity studies. 
Materials and Methods 
Synthesis 
General methods. Melting points were taken on a Thomas-Hoover capillary 
melting point apparatus and are uncorrected. TLC was run on silica 60F-254 
plates (Analtech, Inc.). Detection of components on TLC was made by UV 
light absorption at 254 nm. Ultraviolet spectra were recorded on a Hewlett- 
Packard 8450 A spectrophotometer. IR spectra were taken on a Nicolet 5DXB 
infrared spectrometer. NMR spectra were determined at 270 or 360 MHz with 
a BRUKER WP 270/360 SY. The chemical shift values are expressed in 6 
values (parts per million) relative to the standard chemical shift of the solvent 
DMSO-d6 unless otherwise specified. Elemental analyses were performed by 
M-H-W Laboratories, Phoenix, AZ and are within _+ 0.4% of the theoretical 
values. E. Merck silica gel (230-400 mesh) was used for flash column 
chromatography, which was carried out as described by Still and Kahn (1978). 
Evaporations were carried out under reduced pressure (water aspirator) with 
the bath temperature at 40°C. Acetonitrile was distilled from CaH2. 
1-[2- ( aceto xyetho xy ) methyl]-2-bromo-5- ( ethoxymethylene ) imino-pyrrole-3, 4- 
diearbonitrile (3). A mixture of 2-amino-5-bromo-3,4-dicyanopyrrole 
(Swayze et al., 1991) (1, 2.11 g, 10.0 mmol) and distilled triethylorthoformate 
(2.96 g, 20 mmol) in dry acetonitrile (75 ml) under argon was heated at reflux 
for 2 h, cooled to room temperature and the solvent evaporated in vacuo. The 
resulting residue was co-evaporated with toluene (2 x 100 ml) and rotary 
evaporated until a dry powder was obtained. The 'H NMR spectrum of this 
compound agrees with structure 2:6 13.5 (1H, s, NH), 8.40 (1H, s, CHN), 4.28 
(2H, q, CH3CH20, J = 7.1 Hz), 1.30 (3H, t, CH3CH2, J = 7.1 Hz). Crude 2 was 
dissolved in dry acetonitrile (100 ml) then treated with sodium hydride (60% w/ 
w%, 0.60 g, 15 mmol) at room temperature. The mixture was stirred for 0.5 h, 
then (2-acetoxyethoxy)methyl bromide (Robins and Hatfield, 1982) (3.94 g, 20 
mmol) was added dropwise. The reaction mixture was stirred at room 
temperature for 0.5 h, then filtered. The filtrate was evaporated and the 
resulting oil subjected to flash column chromatography (CHC13) to yield a pale 
yellow oil. The compound was recrystallized from methanol to yield 2.12 g 
(55%) of 3: mp 102-103°; TLC, MeOH/CHC13 (5:95, v:v) Rf = 0.72; FTIR 
(KBr)vmax2227, 1741, 1725, 1613, 1243, 1137, 1111, 1057, 637 cm- l ;  1H NMR 
(CDC13): 6 8.39 (1H, s, CHN), 5.39 (2H, s, C-I'), 4.37 (2H, q, CH3CHzO, 
J=7.1 Hz), 4.16 (2H, t, CH202, J=4.7 Hz), 3.66 (2H, t, OCH2, J=4.7  Hz), 
2.03 (3H, s, CO2CH3), 1.40 (3H, t, CH3CH2, J=7.1 Hz); Anal calcd for 
C14H15N404Br: C, 43.88; H, 3.95; N, 14.62. Found: C, 43.71; H, 4.09; N, 14.80. 
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4-A mino-6-bromo- 7-[ ( 2-hydroxyethoxy ) methyl]pyrrolo[ 2,3-d]pyrimidine-5- 
carbonitrile (4). To 100 ml of saturated methanolic ammonia in a pressure 
bottle at 25°C was added compound 3 (2.60 g, 6.78 mmol). The bottle was 
sealed and the solution stirred for 24 h at room temperature. The resulting 
suspension was cooled to -78°C then filtered to yield 1.89 g (89%) of 4: mp 
235-236°(d); TLC, (40:9:1 EtOAc/MeOH/H20, v:v) Rf = 0.71: UV 1 max (emM) 
(pH 1) 230 (15), 282 (16); (EtOH), 285 (16); (pH 11) 229 (11), 285 (16); FTIR 
(KBr)vmax 3569, 3366, 3329, 3116, 2942, 2225, 1666, 1649, 1596, 1364, 1306, 
1115, 1051, 792 cm ~; IH NMR: 6 8.24 (1H, s, C-2), 7.00 (2H, s, NH2, D20 
exchangeable), 5.62 (2H, s, C-I'), 4.66 (1H, t, OH, D20 exchangeable, J = 5.2 
Hz), 3.49-3.43 (4H, m, CH2); Anal calcd for Cl0HloNsO2Br: C, 38.48; H, 3.23; 
N, 22.45. Found: C, 38.62; H, 3.35; N, 22.55. 
4-A mino- 7-[ (2-hydroxyethoxy) methyl]pyrrolo[2,3-d]pyrimidine-5-carbonitrile 
(5). Compound 4 (2.47 g, 8.0 mmol) was dissolved in a mixture of EtOAc and 
EtOH (2:1 v:v; 150 ml) containing 5 ml of 1 N NH4OH. Palladium-carbon 
(10%; 593 mg) was added, and the reaction mixture was hydrogenated at 42 psi 
at room temperature for 12 h. The mixture was filtered, the filtrate evaporated 
in vacuo and the resulting solid adsorbed onto silica gel (7.5 g) then subjected 
to column chromatography in MeOH/CHC13 (5:95, v:v) to yield 1.19 g 5 
(63%): mp 186-188°; TLC, MeOH/EtOAc/CHC13 (1"1:5, v:v) Rf=0.28; 1H 
NMR: 6 8.34 (1H, s, C-2), 8.23 (1H, s, C-6), 6.90 (2, br s, NH2, D20 
exchangeable), 5.56 (2H, s, C-I'), 4.67 (1H, s, OH, D20 exchangeable), 3.44 
(4H, m, CH2). All other spectroscopic data obtained for compound 5 was 
identical to that previously reported (Gupta et al., 1989a). A sample was 
recrystallized from EtOH for analysis: Anal calcd for C~0H~ ~N502: C, 51.49; H, 
4.75; N, 30.03. Found: C, 51.46; H, 4.77; N, 30.08. 
4-Am ino- 7-[ ( 2-hydroxyethoxy ) methyl]pyrrolo[ 2,3-d]pyrimidine-5- 
thiocarboxamide (229). Dry HzS was passed through a solution of sodium 
methoxide (1.5 g, 28 mmol) in dry methanol (300 ml) for 0.5 h. The nitrile 5 
(3.25 g, 13.9 retool) was added in one portion, and the mixture was stirred in a 
sealed pressure vessel at 80°C for 1.5 h. The resulting solution was allowed to 
cool to room temperature, then adjusted to pH 7 with 1 N HC1. The solvent 
was rotary evaporated and the compound recrystallized from H20 containing a 
small amount of EtOH to yield 1.68 g of 229 (45%): mp 199-200°; TLC, 
MeOH/CHC13 (5:95, v:v) Rf=0.17; 1H NMR: 6 9.49 and 9.52 (1 each, br s, 
CSNH2, D20 exchangeable), 8.14 (1H, s, C-2), 7.93 (2H, s, NH2, D20 
exchangeable), 7.86 (1H, s, C-6), 5.54 (2H, s, C-I'), 4.69 (1H, s, OH, D20 
exchangeable), 3.47 (4H, m, CH2). All other spectroscopic data obtained for 
compound 229 was identical to that previously reported (Gupta et al., 1989a); 
Anal calcd for C~0H13NsO2S: C, 44.93; H, 4.90; N, 26.20. Found: C, 44.73; H, 
4.79; N, 26.31. 
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Cell cultures 
KB cells, an established human cell line derived from an epidermal oral 
carcinoma, were routinely grown in MEM with Hanks' salts [MEM(H)] 
supplemented with 10% calf serum. Diploid cell cultures of HFF cells were 
grown in MEM with Earle salts [MEM(E)] supplemented with 10% fetal 
bovine serum. Cells were passaged by conventional procedures by using 0.05% 
trypsin and 0.02% EDTA in a HEPES (N-2-hydroxyethylpiperazine-N'-2- 
ethanesulfonic acid)-buffered salt solution (HBS) (Shipman et al., 1976). To 
increase the likelihood of detecting bacterial or mixed bacterial and 
mycoplasmal contamination, antibiotics were never used in the routine 
passage of cells (Hayflick, 1973). Cell lines were screened periodically and 
were mycoplasma-free. 
Antiviral assays 
The effect of compound 229 and DHPG on HCMV replication was 
determined by plaque and yield reduction assays. HCMV plaque reduction 
assays were performed with monolayer cultures of HFF cells. A plaque purified 
isolate, Po, of the Towne strain of HCMV obtained from Dr. M.F. Stinski, 
University of Iowa, was used. Preparation of HCMV stocks and the plaque 
assay are detailed elsewhere (Turk et al., 1987). The virus inoculum contained 
approximately 100 PFU of HCMV. Selected concentrations of the compound 
were dissolved in the medium and added 1 h after addition of virus. At 10-12 
days plaques were enumerated microscopically at a magnification of 30-fold. 
Yield (titer) reduction assays were performed as reported previously (Prichard 
et al., 1990). Monolayer cultures of HFF cells were infected at a multiplicity of 
infection of 0.5 PFU per cell and incubated in the presence of test compounds 
for 7-10 days. Following three cycles of freezing at -76°C  and thawing at 
37°C, the resulting lysates were diluted and the amount of infectious virus was 
quantitated on new cultures of HFF cells. 
The activity of compounds against other herpes viruses was determined by 
plaque assay. The susceptibility of MCMV (Smith strain) to antiviral drugs was 
assayed by plaque assay in primary mouse embryo fibroblasts. The sensitivity 
of HSV-1 (E-377 strain), HSV-2 (MS strain), and VZV (Ellen strain) to 
compounds was determined in HFF cells by the plaque reduction assay. 
Confluent cell monolayers in 6-well plates were inoculated with 20-50 PFU of 
the appropriate virus and incubated at 37°C and 90% humidity for 1 h. Serial 
5-fold dilutions of each drug were prepared in twice concentrated MEM(E), 
mixed with an equal volume of a 1% agarose and 2 ml of the mixture added to 
the monolayer cultures. An additional overlay mixture without drug (1 ml) was 
added on day 4 for MCMV and on days 3 and 6 for VZV. At the appropriate 
time (HSV, 3 days; MCMV, 7 days; VZV, 10 days) monolayers were stained 
with neutral red and plaques enumerated either visually or with the aid of a 
stereo dissecting microscope. Drug-treated cultures were compared to 
untreated control cultures and ICs0 values were calculated using a dose-effect 
analysis software program (Elsevier-Biosoft, Cambridge, U.K.). 
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Cell growth rates 
The inhibitory effect of  compound 229 on KB cell growth was studied and 
population doubling time and cell viability were determined as detailed 
elsewhere (Nassiri et al., 1990). Briefly, 6-well plastic tissue culture dishes were 
seeded with 80,000 or 100,000 cells per well. Approximately 24 h later, the 
medium from the wells was aspirated and fresh medium with or without 
selected concentrations of drug was added. The incubation period was 
continued to 96 or 120 h at 37°C. Every 24 h, cultures were harvested by 
means of 0.05% trypsin plus 0.02% EDTA in HBS. Cells were enumerated by 
using a Coulter Counter (model ZF, Coulter Electronics, Hialeah, FL). 
Viability of untreated cultures were periodically checked by trypan blue dye 
exclusion. Control cells showed a viability of > 95%. Population doubling 
times were calculated by means of a least squares program fitting the 
exponential portion of the growth curve. 
Plating efficiency 
Plating efficiencies were carried out by procedures described earlier (Nassiri 
et al., 1991a). Briefly, KB cells were diluted with medium and planted in tissue 
culture dishes (150 x 25 mm, Falcon, Oxnard, CA) for a final concentration of 
500-650 cells per dish. After an incubation period of 12-14 days, medium was 
removed and cells were rinsed with buffer solution then fixed with absolute 
methanol. After 2 rain, the cells were stained with 0.1% crystal violet and 
clones > 1 mm in diameter were enumerated. 
Flow cytometry 
DNA-flow cytometry was carried out by procedures outlined earlier (Nassiri 
et al., 1990) with several modifications to be detailed elsewhere (Nassiri et al., 
manuscript in preparation). Briefly, untreated and drug-treated HFF cells were 
fixed in 70% ethanol for a minimum of 24 h. When ready for flow cytometric 
analysis, the cells were pelleted and resuspended in 500 ~1 of DNase (1 mg/ml of 
2340 U/mg, Sigma, St. Louis, MO) per l06 cells and incubated at 37°C for 45 
min. 100 #1 of 1 mg/ml propidium iodide reagent (PI, Sigma, St. Louis, MO) 
was added to the suspension containing 1 x 106 cells which was chilled on ice 
water for 60 rain. Propidium stained nuclei were analyzed on an EPICS V Flow 
Cytometer fitted with an argon-ion laser emitting at 488 nm (400 mW), a 515 
nm long pass filter, a 560 nm dichroic filter and a 630 nm long pass filter (red, 
DNA). Chicken erythrocytes were added in amounts equal to 20% of each 
sample preparation as internal biological standards. In all samples, a total of  
10,000 nuclei were analyzed. Percentage estimates of cells in G0/Gl, S and G2/ 
M phases were made using an integration software analysis package provided 
with the flow cytometer for the Easy II computer (Coulter Electronics, Hialeah, 
FL). 
Data analysis 
Dose-response relationships were used to quantitate drug effects. These were 
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constructed by linearly regressing the percent inhibition of parameters derived 
in the preceding sections against log drug concentrations. The 50% inhibitory 
(IC5o) concentrations were calculated from the regression lines using the 
methods described by Goldstein (1964). Ganciclovir (DHPG; kindly provided 




The original synthesis of compound 229 (Gupta et al., 1989a) was not 
suitable for multi-gram synthesis and the first step in the reaction scheme itself 
resulted in an isomeric mixture of alkylated products. We have utilized the 
approach of Ramasamy (1986) which fixes the site of alkylation on the pyrrole 
and have also reduced the total steps in the synthesis of compound 229 (Fig. 1). 
The alkylated pyrrole 3 was obtained in 55% yield by treatment of the known 
pyrrole (Swayze et al., 1991) (1) with triethylorthoformate followed by the 
addition of sodium hydride and (2-acetoxyethoxy)methyl bromide (Robins and 
Hatfield, 1982). Ring annulation and removal of the protecting group was 
achieved with saturated methanolic ammonia in a pressure bottle at room 
temperature to give 4 in excellent yield (89%). Debromination of 4 via catalytic 
hydrogenation gave 5 which, when treated with methanolic sodium 
hydrosulfide generated in situ, gave 229 in a two-step yield of 28%. The 
overall yield for the new synthesis of compound 229 was 14% compared to the 
original value of 0.6% (Gupta et al., 1989a). Subsequent runs on a smaller scale 
have given compound 229 in yields of approximately 40% from 1. 
Biological evaluation 
Antiviral activity. In our initial studies, compound 229 was moderately active 
against HCMV in plaque-reduction assays with an IC50 of 11 #M (Gupta et al., 
1989a). In three separate experiments in the current study the average activity 
TABLE 1 
Activity of compound 229 against selected herpesviruses 
Virus Cell line a 50% inhibitory concentration (#M) b 
Compound 229 Ganciclovir Acyclovir 
HCMV human foreskin fibroblasts 7 10 
MCMV mouse embryo fibroblasts 16 2.6 
HSV-1 human foreskin fibroblasts 21 
HSV-2 human foreskin fibroblasts 30 




aUsed to propagate the virus and assess visual cytotoxicity. 
bVirus strains and plaque assays described in the text, average of two or more experiments. 
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Fig. 1. Synthesis of 4_amino-7-[(2-hydroxyethoxy)methyl]pyrrolo[2,3-d]pyrimidine-5-thiocarboxamide 
(compound 229). Numbered reactants are as follows: i. CH(OEt)3, CH3CN ii. Nail,  (2-acet- 
oxyethoxy)methyl bromide iii. NH3, MeOH iv. Pd/C (10%), H2 v. NaOMe, MeOH and H2S. 
against HCMV in a plaque reduction assay was 7 #M for compound 229 and 
10 #M for ganciclovir (Table 1). Compound 229 was somewhat less active than 
TABLE 2 
Population doubling times of KB cells treated with compound 229 a 
Concentration of compound 229 (#M) 0 10 32 100 100 (reversal) 
Population doubling time (h) 21.0 21.5 23.5 34.7 23.9 
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Fig. 2. Effect of  compound 229 and D H P G  on the replication of HCMV. Subconfluent monolayers of  
H F F  cells were infected at a multiplicity of  infection of 0.5 PFU per cell and incubated in the presence of  
test compounds  for 7 days. Infectious virus present at that time was quantitated by plaque assay on HFF  
cells as described in the text, Average data from two experiments are presented. 
ganciclovir against MCMV and was least active against HSV-1, HSV-2 and 
VZV (Table 1). In previous work (Gupta et al., 1989a), we found slight activity 
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Fig. 3. Reversibility of  inhibition of KB cell growth by compound 229. Cells were seeded at 80,000 cells per 
well and incubated for 24 h at which time 100 #M compound 229 was added to two sets of  cultures (O,  O)  
and incubated for an additional 24 h. At that time, medium was removed from one set of  drug-containing 
cultures (O)  and following a rinse with medium, the cultures were incubated with drug free medium. Cells 
were subsequently harvested at selected time periods up to 120 h and enumerated with a Coulter counter. 
Inset: plot (as percent of  cells in control cultures) 'of total KB cells in cultures continually treated with 100 
/~M compound 229 ( 0 )  and cultures from which drug was removed after 24 h (O). Similar results were 
obtained in two separate experiments. 
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Fig. 4. Flow histograms illustrating the response of HFF ceils to 100/~M compound 229 for 24 and 48 h. 
Percentages of G0/G1, S and G2/M were determined as described in the text: Control, 24 h: G0/G~, 54; S, 
27; G2/M, 19. Compound 229, 24 h: G0/G~, 53; S, 33; G2/M, 14. Control 48 h: G0/G~, 64; S, 24; G2/M, 12. 
Compound 229 48 h: G0/G> 65; S, 28; G2/M, 7. 
compound 229 was less active than ganciclovir in yield reduction experiments 
(Fig. 2) ( I C 9 0  = 25 #M vs. 1 #M, respectively). Compound 229 reduced HCMV 
titer by more than three logt0 units (> 1000-fold) at 100 #M compared to a 
greater than four lOgl0 reduction by ganciclovir. 
Effects on uninfected cells. The effect of compound 229 on the growth of 
uninfected KB cells was examined as a measure of drug cytotoxicity. 
Compound 229 slightly suppressed the growth of KB cells at 10 and 32 /~M. 
Population doubling times increased from 21 h in the control to 21.5 h with 10 
/~M and 23.5 h with 32/~M (Table 2). Cells continued to grow at concentrations 
up to 100/~M, where the population doubling time increased to 34.7 h. Cells 
did not grow in the presence of 320 #M. 
The inhibition observed at 100 #M was reversible upon removal of the drug 
following a 24 h incubation period (Fig. 3).After the removal of compound 
229, cell growth recovered to a population doubling time of 23.9 h (Table 2). 
This is more obvious in the inset which shows that the percentage of KB cells 
treated with 100 #M compound 229 increased after the removal of the 
compound, whereas the number of cells in the treated cultures continued to 
decline. 
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The ability of KB cells to attach to a substrate and clone in the presence of 
selected concentrations of compound 229 and DHPG was evaluated. We have 
found plating efficiency to be a technique often more sensitive than cell growth 
to evaluate cytotoxicity. Compound 229 had an IC50 value of 23/aM compared 
to an IC50 of 51 pM for ganciclovir (data not shown). 
As an additional and detailed measure of cytotoxicity, perturbations in the 
cell cycle caused by compound 229 were measured by utilizing DNA flow 
cytometry (Barlogie et al., 1983; Gray and Coffino, 1979; Nassiri et al., 1990). 
Incubation of 100 #M compound 229 for 24 and 48 h with HFF cells resulted in 
an accumulation of cells in early S phase with a concurrent reduction of cells in 
G2/M phase (Fig. 4). These data are consistent with an early S phase blockage 
and with the cell growth studies which showed inhibition of cell growth at 100 
#M. The effect of 100 pM compound 229 on the cell cycle of KB cells was 
essentially the same as HFF cells at 12, 36, 48 and 72 h of treatment (data not 
shown). Concentrations of I0 and 32 pM over similar time periods showed no 
significant perturbations in the cycle of KB cells compared to control (data not 
shown). In other flow cytometry studies, we found that ganciclovir had a minor 
effect on the KB cell cycle at 100 pM. There appeared to be a 4% decrease in 
the total number of cells in G0/G1 with a similar increase in the number of cells 
in S phase. These effects, however, were not statistically significant by Student's 
t-test. 
Discussion 
In the present study, we have described the multi-gram synthesis of an 
acyclic analog of thiosangivamycin; examined or re-examined the activity 
against selected herpesviruses including HCMV, MCMV, HSV-1, HSV-2 and 
VZV; and evaluated the cytotoxicity of the compound in uninfected cells using 
cell growth studies, plating efficiency and DNA flow cytometry. In cell growth 
experiments, the inhibitory effect of this compound was not immediate and did 
not dramatically affect the growth of KB cells up to 100 #M. But even this 
effect was reversible, suggesting that compound 229 is acting as a cytostatic 
rather than a cytotoxic agent. This raises the possibility that the compound 
may inhibit DNA polymerase rather than be a substrate and act as a chain 
terminator. 
Flow cytometry results from two separate cell lines suggest that compound 
229 may be interfering with the progression of cells through S phase since there 
is an increase in the percentage of cells S phase coupled with a loss of cells in 
G2/M. The overall cell cycle perturbation was modest. Interestingly, two other 
acyclic 4-amino-5-substituted pyrrolo[2,3-d]pyrimidines act as S phase blockers 
(Nassiri et al., 1990). These compounds are 5-bromotubercidin analogs which 
differ from compound 229 in that .one is an acyclovir analog (4-amino-5- 
bromo-7-[(2-hydroxyethoxy)methyl]pyrrolo[2,3-d]pyrimidine, compound 102) 
and the other a ganciclovir analog (4-amino-5-bromo-7-[(1,3-dihydroxy-2- 
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propoxy)methyl]pyrrolo[2,3-d]pyrimidine, compound 183). Like compound 
229, the effects of compound 102 on uninfected cells were reversible upon 
removal of the compound, whereas the removal of compound 183 did not 
reverse growth inhibition. Furthermore, cells treated with compound 229 
morphologically resembled those treated with compound 102, not compound 
183. Unlike compound 229, compound 102 blocked the progression of the cell 
cycle at mid S phase whereas, like compound 229, compound 183 blocked cells 
at late G0/G~ and early S phase. The inhibitory effects of both compounds 102 
and 183, though, were observed at 10/tM compared to 100/~M for compound 
229. Based upon these comparisons, compound 229 may be acting by a cellular 
mechanism which is different from either compound 102 or 183 even though all 
three are pyrrolo[2,3-d]pyrimidine analogs. The exact mechanism underlying 
this phenomenon is under investigation. 
Although compound 229 was not as efficacious as ganciclovir in yield 
reduction assays against HCMV and was slightly more cytotoxic, this study 
provides insights into a new class of pyrrolo[2,3-d]pyrimidines which are 
worthy of further investigation. 
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